ライフサイエンスコーパス: valproate

1 psychosis with the use of divalproex sodium (valproate).

2 s (carbamazepine, lamotrigine, phenytoin and valproate).

3 , ameliorated by antimania drugs lithium and valproate.

4 ection against suicidal behavior compared to valproate.

5 ypically responsive to treatment with sodium valproate.

6 ileptic agents phenytoin, phenobarbital, and valproate.

7 .71 (0.51-1.00, p=0.0472) for lithium versus valproate.

8 r mood-stabilizing drugs such as lithium and valproate.

9 o carbamazepine, and 92 for those exposed to valproate.

10 ment of the child exposed in utero to sodium valproate.

11 or phenytoin but not among those exposed to valproate.

12 ntrations of the HDACIs vorinostat or sodium valproate.

13 expressing MLL-PTD(+) AML cells treated with valproate.

14 ts of the mood-stabilizing drugs lithium and valproate.

15 as its water-soluble anionic conjugate base valproate.

16 king olanzapine, risperidone, quetiapine, or valproate.

17 tol biosynthetic pathway by both lithium and valproate.

18 associated with fewer MCMs than all doses of valproate.

19 d to therapeutic levels of either lithium or valproate.

20 antage, and partially rescued sensitivity to valproate.

21 od autism among 6152 children not exposed to valproate.

22 ne, flunarizine, pizotifen, propranolol, and valproate.

23 2005 to 2013 for treatment with lithium and valproate.

24 s in common clinical use--lithium and sodium valproate.

25 r older AEDs namely carbamazepine and sodium valproate.

26 ine and histone deacetylase inhibitor sodium valproate.

27 evant concentration of the anti-bipolar drug valproate (0.6 mm).

28 83, p=0.0023) for combination therapy versus valproate, 0.82 (0.58-1.17, p=0.27) for combination ther

29 in (five), clavulanate/amoxicillin (15), and valproate (11).

30 ith 2148 prescribed lithium, 1670 prescribed valproate, 1477 prescribed olanzapine, and 1376 prescrib

31 Valproate (2-propylpentanoate) is a commonly used mood s

32 nt was started at age 26 years or older (24% valproate, 22% lamotrigine).

33 treatment at age younger than 26 years (44% valproate, 23% lamotrigine; p = 0.002) but was similar i

34 = 0.010) and the post hoc (HA) analyses (36% valproate, 23% lamotrigine; p = 0.007).

35 The highest doses of valproate (300 mg/kg) and lamotrigine (30 mg/kg) also el

36 mood stabilizer (lithium, carbamazepine, or valproate), 37 patients were randomly assigned to 6 mont

37 e lamotrigine (59 [83%] of 71; p=0.0287) and valproate (38 [79%] of 40; p=0.0089) groups.

38 group developed (OD) in the prospective (54% valproate, 38% lamotrigine; p = 0.010) and the post hoc

39 risk [PYAR]) compared with those prescribed valproate (392; 95% CI, 334-460 per 10000 PYAR), olanzap

40 .5 mg/kg; s.c. ), or (3) five daily doses of valproate (50 mg/kg, i.p.) 1 h prior to MPD (2.5 mg/kg,

41 cutive days (Days 3-8), (2) a single dose of valproate (50 mg/kg; i.p.) 1 h prior to the first (Day 3

42 Moreover, the GHB dehydrogenase inhibitor valproate (500 mg/kg, intraperitoneal), which inhibits t

43 to the inositol-depleting drugs lithium and valproate, a loss of function allele of TPI1 was identif

44 Together, these data demonstrate that valproate activates the ERK pathway and induces ERK path

45 Treatment with lithium and valproate activates the extracellular signal-regulated k

46 ined the occurrence of thrombocytopenia with valproate administration.

47 Although valproate affects the functions of GSK-3 (glycogen synth

48 Valproate also enhanced the rate of the partial steps in

49 Valproate also promoted neural stem cell proliferation-m

50 Valproate amide 3 is orally bioavailable and releases ge

51 le taking study medication; 42 (27 receiving valproate and 15 receiving placebo) reached 24 months ha

52 A total of 122 participants (59 receiving valproate and 63 receiving placebo) completed 24 months

53 previously reported the effects of lithium, valproate and a new antipsychotic, paliperidone on prote

54 ttenuation of phosphorylation by lithium and valproate and also brought GluR1 back to the surface, su

55 of SZ patients treated with a combination of valproate and APS in which the expression of DNMT1 faile

56 nts with psychosis received a combination of valproate and APS treatment but not APS monotherapy.

57 Some mood stabilizers, e.g., sodium valproate and carbamazepine, are human teratogens.

58 n of LY379268 on Gadd45-beta was mimicked by valproate and clozapine but not haloperidol.

59 h lower verbal and non-verbal abilities with valproate and for lower verbal abilities with carbamazep

60 there was no significant difference between valproate and lamotrigine (1.25 [0.94-1.68]).

61 ld have effects similar to or different from valproate and lamotrigine in a model of reward and eleva

62 drugs developed as anticonvulsants (notably, valproate and lamotrigine) have therapeutic effects in b

63 ight on the possible mechanisms of action of valproate and lithium in the treatment of the disease.

64 , both combination therapy with lithium plus valproate and lithium monotherapy are more likely to pre

65 both at basal levels and in the presence of valproate and lithium.

66 Lithium, valproate and paliperidone had a substantial and common

67 daily intraperitoneal injections of lithium, valproate and paliperidone.

68 iazepines like clobazam, in combination with valproate and stiripentol, provides only modest seizure

69 there was no significant difference between valproate and topiramate in either the analysis overall

70 bilizers (lithium, carbamazepine, and sodium valproate) and plasma levels of these drugs to future ps

71 ion of antimanic treatments such as lithium, valproate, and carbamazepine.

72 drug monotherapy (phenytoin, carbamazepine, valproate, and lamotrigine).

73 Lithium, valproate, and olanzapine had unequivocal evidence for e

74 ns with the epigenetic drugs azacytidine and valproate, and tested tumor and self-reactivities of the

75 The anticancer activity of valproate appears to be driven by histone deacetylase in

76 ug Administration-approved drugs lithium and valproate are not completely effective in the treatment

77 Both lithium and valproate are well-established treatments for bipolar di

78 ar disorder (carbamazepine, lamotrigine, and valproate) are associated with an elevated risk of suici

79 us effectiveness of lamotrigine, topiramate, valproate, aripiprazole, olanzapine, and omega-3 fatty a

80 Propranolol was compared with valproate as well as behavioral treatment, and 2 studies

81 depressed), and treatment group (placebo or valproate) as covariates.

82 In utero exposure to valproate, as compared with other commonly used antiepil

83 ic function and on doses and serum levels of valproate at sequential intervals over a 12-month period

84 f purified MIP synthase was not inhibited by valproate at this concentration, suggesting that inhibit

85 tional studies showed that either lithium or valproate, at therapeutically relevant levels, inhibited

86 ghly dissimilar mood stabilizers lithium and valproate: BAG-1 [BCL-2 (B-cell CLL/lymphoma 2)-associat

87 Sodium valproate, benzodiazepines and topiramate were reported

88 y (carbamazepine, lamotrigine, phenytoin, or valproate) between October, 1999, and February, 2004, at

89 Finally, valproate, but not lithium, increases expression of phos

90 The mood-stabilizing drug valproate, but not lithium, rescues the manic-like behav

91 for pregnancies exposed to <600 mg daily of valproate, but this was not significant (3.4% vs 5.0%, p

92 thus explored the structural optimization of valproate, butyrate, phenylacetate, and phenylbutyrate b

93 e risk of MCMs after monotherapy exposure to valproate, carbamazepine and lamotrigine.

94 In utero exposure to valproate carries a significantly higher MCM risk than l

95 Lithium and valproate cause a decrease in intracellular myo-inositol

96 D sensitization while repeated injections of valproate co-administered with MPD treatment completely

97 We found that lithium and valproate, commonly used mood stabilizers for the treatm

98 001 [adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs]), drug dosage (regres

99 trations in subjects taking carbamazepine or valproate compared with those taking other antiepileptic

100 0.80-0.99 mEq/L) or divalproex (target serum valproate concentration, 80-99 mug/mL) for 9 weeks.

101 Doses were adjusted to maintain steady serum valproate concentrations.

102 sponse to the histone deacetylase inhibitor, valproate, consistent with the encoded protein-SMCT1-sho

103 latory failure included IGE syndrome, use of valproate currently or within 3 years, high free testost

104 Of women using valproate currently or within the preceding 3 years, 38.

105 Lorazepam, modafinil, and valproate did not influence P50 suppression in low gater

106 Risperidone, amisulpride, and valproate did not influence PPI.

107 Children exposed to valproate did poorly on measures of verbal and memory ab

108 Performance was negatively associated with valproate dose for both verbal and non-verbal domains an

109 as found to be repressed by steatotic drugs (valproate, doxycycline, tetracycline, and cyclosporin A)

110 rs were used to identify children exposed to valproate during pregnancy and diagnosed with autism spe

111 Maternal use of valproate during pregnancy was associated with a signifi

112 ecause of known potential adverse effects of valproate during pregnancy, the benefits for seizure con

113 ders (quetiapine, olanzapine, and semisodium valproate) during the same period (retrospectively assig

114 Similar to neurotrophic factors, valproate enhanced ERK pathway-dependent cortical neuron

115 Chronic treatment with valproate enhanced neurogenesis in the dentate gyrus of

116 In the presence of GABA, however, valproate enhanced the GABA-evoked steady-state inward c

117 The valproate enhancement did not alter the Na(+) or Cl(-) d

118 ments under voltage clamp suggested that the valproate enhancement of the GABA-evoked current was mat

119 Fetal valproate exposure has dose-dependent associations with

120 We previously reported that foetal valproate exposure impairs intelligence quotient.

121 2 rats were also re-challenged with 50 mg/kg valproate followed by 2.5 mg/kg MPD 1 h later on Day 15.

122 igine has a favourable profile compared with valproate for adverse pregnancy outcomes, the requiremen

123 response and that the target blood level of valproate for best response in acute mania is above 94 m

124 the treatment benefits for women who require valproate for epilepsy control.

125 agent, as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression.

126 el, only phenytoin proved ineffective, while valproate, gabapentin and carbamazepine varied in their

127 that several antiepileptic agents, including valproate, gabapentin and phenytoin, reduced the ability

128 In conclusion, a single injection 50 mg/kg valproate given prior to any MPD treatment partially blo

129 he lithium group, and 76 (69%) of 110 in the valproate group had a primary outcome event during follo

130 The valproate group had a significantly lower proportion of

131 The valproate group had higher rates of somnolence, gait dis

132 cation adherence was added as covariate, the valproate group had significantly fewer drinks per heavy

133 imaging scans at baseline and 12 months; the valproate group showed greater loss in hippocampal and w

134 More women in the valproate group than the lamotrigine group developed (OD

135 More women in the valproate group than the lamotrigine group developed PCO

136 igher in the placebo group compared with the valproate group.

137 ix from the lithium group and eight from the valproate group.

138 our study overall and in the lamotrigine and valproate groups.

139 Overall, the 508 children exposed to valproate had an absolute risk of 4.42% (95% CI, 2.59%-7

140 On average, children exposed to valproate had an IQ score 9 points lower than the score

141 Lithium reduced impulsivity, whereas valproate had no effect on choice behavior.

142 lind trial of ethosuximide, lamotrigine, and valproate had short-term seizure outcome determined.

143 Sodium valproate has been a first-line antiepileptic drug for 4

144 While valproate has been implicated as having particularly not

145 Prescribing of carbamazepine and sodium valproate have declined since 1994 despite being the mos

146 ing for clustering by primary care practice (valproate hazard ratio [HR] 0.56; 95% confidence interva

147 Valproate, however, has been found to exert an antiproli

148 Rates of new onset hyperthyroidism (valproate HR 0.24; 95% CI 0.09-0.61; p = 0.003, olanzapi

149 CI 0.13-0.73; p = 0.007) and hypercalcemia (valproate HR 0.25; 95% CI 0.10-0.60; p = 0.002, olanzapi

150 ate, olanzapine, and quetiapine were higher (valproate HR 1.62; 95% CI 1.31-2.01; p < 0.001, olanzapi

151 Hypothyroidism was reduced in those taking valproate (HR 0.60; 95% CI 0.40-0.89; p = 0.012) and ola

152 y rates were lower for lithium compared with valproate (HR, 1.32; 95% CI, 1.10-1.58) and quetiapine (

153 tiagabine (HR, 2.41; 95% CI, 1.65-3.52), and valproate (HR, 1.65; 95% CI, 1.25-2.19), compared with t

154 d, placebo-controlled trial of flexible-dose valproate in 313 (of 513 screened) individuals with mode

155 re are now preliminary reports of the use of valproate in human haematological and solid tumours.

156 g treatment with lamotrigine, topiramate and valproate in patients diagnosed with generalised or uncl

157 e, whereas apoptosis occurred in response to valproate in PELs that supported lytic replication of HH

158 ildhood autism in children after exposure to valproate in pregnancy.

159 rovide evidence that incubation of PELs with valproate in the presence of ganciclovir or PFA can sele

160 We tested lacosamide, lamotrigine, and valproate in the rat ICSS test alone or in the presence

161 es to identify common targets of lithium and valproate in the yeast Saccharomyces cerevisiae.

162 l detected no difference between lithium and valproate in time to suicide attempt or suicide event in

163 ars of age, children who had been exposed to valproate in utero had significantly lower IQ scores tha

164 l difficulties in children exposed to sodium valproate in utero.

165 t (carbamazepine, lamotrigine, phenytoin, or valproate) in a prospective, observational, multicenter

166 ility of the anticonvulsant mood stabilizer, valproate, in bipolar disorder with co-occurring alcohol

167 The same dose of valproate increased acetylation of histone H3 in mouse b

168 We found that chronic treatment of rats with valproate increased levels of activated phospho-ERK44/42

169 We propose that valproate increases the turnover rate of GABA transporte

170 al models, and butyrate, phenylbutyrate, and valproate induce gamma globin in human patients.

171 Ganciclovir and PFA also prevented most valproate-induced expression of the late lytic viral tra

172 terior cingulate, a region in which we found valproate-induced increases in expression of an ERK path

173 lovir and phosphonoformic acid (PFA) blocked valproate-induced production of infectious virus without

174 Valproate is an important anticonvulsant currently in cl

175 Valproate is better tolerated than topiramate and more e

176 Uptake experiments indicated that valproate is not transported by mouse GAT3 in the absenc

177 registers has not only confirmed that sodium valproate is teratogenic but also that it may be associa

178 neurologists had long suspected--that sodium valproate is the most effective drug in the treatment of

179 Valproate is used for the treatment of epilepsy and othe

180 Valproate is widely accepted as a drug of first choice f

181 Another older AED, valproate, is associated with the occurrence of polycyst

182 not cotreatment, with interferon attenuators valproate, Jak1 inhibitor, or vaccinia virus B18R protei

183 er mood-stabilizing treatments of BD such as valproate, lamotrigine, carbamazepine, oxcarbazepine, an

184 Patients were randomly assigned to valproate, lamotrigine, or topiramate between Jan 12, 19

185 Consistent with this possibility, growth in valproate leads to decreased synthesis of inositol monop

186 the presence of the inositol-depleting drug valproate led to an increase in phosphatidylglycerophosp

187 e with that of placebo as well as the lowest valproate level (< =55.0 microg/ml).

188 The mean serum valproate level was then determined for all subjects wit

189 ies have shown that achieving adequate serum valproate levels is critical to rapid stabilization of a

190 71.4-85.0 microg/ml range and for all higher valproate levels; the 94.1-107.0 and >107.0 microg/ml gr

191 pilepticus) modern treatment choices include valproate, levetiracetam and lacosamide.

192 pileptic agents such as topiramate, disodium valproate, levetiracetam, the antihistamine cyproheptadi

193 ggest that at its therapeutic concentration, valproate may enhance the activity of neuronal and glial

194 Valproate may enhance transcription and reverse SMN2 spl

195 However, prenatal exposure to valproate may increase the risk of autism.

196 ithium but not by valproate, suggesting that valproate may inhibit the Ino1p-catalyzed synthesis of i

197 ed that age-6 IQ was lower after exposure to valproate (mean 97, 95% CI 94-101) than to carbamazepine

198 plasma concentration 0.4-1.0 mmol/L, n=110), valproate monotherapy (750-1250 mg, n=110), or both agen

199 events after randomisation: seven receiving valproate monotherapy (three deaths); five lithium monot

200 The MCM risk with valproate monotherapy exposure in utero was 6.7% (95% CI

201 1290 women were exposed to valproate monotherapy, 1718 to carbamazepine monotherapy

202 y are more likely to prevent relapse than is valproate monotherapy.

203 ls; and Group V, 7 patients receiving sodium valproate monotherapy.

204 rder and were prescribed lithium (n = 2148), valproate (n = 1670), olanzapine (n = 1477), or quetiapi

205 Participants were randomized to 12 months of valproate (n = 225) or lamotrigine (n = 222) therapy.

206 pride and lorazepam (n=30), or modafinil and valproate (n=30), and placebo.

207 This finding supports a recommendation that valproate not be used as a first-choice drug in women of

208 azid, phenytoin, clavulanate/amoxicillin, or valproate occurring since 1994.

209 to patients prescribed lithium, those taking valproate, olanzapine, and quetiapine had reduced rates

210 er, rates of greater than 15% weight gain on valproate, olanzapine, and quetiapine were higher (valpr

211 e event rates during treatment with lithium, valproate, olanzapine, and quetiapine.

212 ipolar disorder who were prescribed lithium, valproate, olanzapine, or quetiapine as maintenance mood

213 zard ratio [HR], 1.40; 95% CI, 1.12-1.74 for valproate, olanzapine, or quetiapine vs lithium) and PS

214 acer uptake methods to examine the effect of valproate on a gamma-aminobutyric acid (GABA) transporte

215 ssessed effects of treatment with lithium or valproate on cognitive impulsivity in selectively bred m

216 nd either valproate or lithium compared with valproate or lithium alone in treating acute manic or mi

217 Compared with the use of valproate or lithium alone, the addition of olanzapine p

218 combined therapy with olanzapine and either valproate or lithium compared with valproate or lithium

219 nterventions, and were randomized to receive valproate or placebo.

220 with high seizure frequency and in those on valproate or polytherapy.

221 acid's, their related drug-congeners (e.g., valproate) or even diet-derived butyrate (from fermentat

222 ntiepileptic (carbamazepine, lamotrigine, or valproate) or not exposed to an antiepileptic, an antide

223 and phenobarbital), a cP450 inhibiting AED (valproate), or an AED that does not alter cP450 enzymes

224 ds immediacy, and then treated with lithium, valproate, or control chow.

225 A significant dose effect was seen with valproate (p=0.0006) and carbamazepine (p=0.03) exposed

226 Thus, both lithium and valproate perturb regulation of the inositol biosyntheti

227 ndomly assigned to treatment with lithium or valproate, plus adjunctive medications as indicated, in

228 Ketogenic diet, diazepam, valproate, potassium bromide and stiripentol attenuate m

229 Topiramate, valproate, propranolol, amitriptyline, and methysergide

230 intained on therapeutic levels of lithium or valproate received a single intravenous infusion of eith

231 intained at therapeutic levels of lithium or valproate received an intravenous infusion of either ket

232 ically relevant concentrations of lithium or valproate reduced hippocampal synaptosomal GluR1 levels.

233 ion of seizures by the common antiepileptic, valproate, reduced the overlap of astrocytic processes.

234 hly dissimilar, antimanic agents lithium and valproate regulate synaptic expression of AMPA receptor

235 -12.66; RR 2.58, 1.33-5.39), or lithium plus valproate (RR 5.95, 1.02-33.33; RR 4.09, 1.01-16.96).

236 ubtedly a phamacogenetic component to sodium valproate's teratogenic and neurodevelopmental effects.

237 Lithium carbonate and valproate semisodium are both recommended as monotherapy

238 that there is a linear relationship between valproate serum concentration and response and that the

239 Higher valproate serum concentration significantly correlated w

240 microg/ml groups were superior to the lowest valproate serum level group.

241 =374) were stratified into seven groups (six valproate serum level ranges and placebo), and effect si

242 ent with lurasidone adjunctive to lithium or valproate significantly improved depressive symptoms and

243 d with fewer migraine headaches per month vs valproate (standardized mean difference [SMD], -0.20; 95

244 In valproate subjects, no common polymorphisms were associa

245 showed that MIPS is indirectly inhibited by valproate, suggesting that the enzyme is post-translatio

246 o inhibition of growth by lithium but not by valproate, suggesting that valproate may inhibit the Ino

247 ects receiving carbamazepine, phenytoin, and valproate than in those receiving lamotrigine (p = 0.008

248 Development of HA was more frequent with OD valproate than lamotrigine among those initiating treatm

249 elopment of HA occurred more frequently with valproate than lamotrigine, especially if medication was

250 Lithium and valproate, the drugs presently used to treat mania assoc

251 Findings regarding the effect of valproate, the most common alternative to lithium, are i

252 Valproate therapy decreases heavy drinking in patients w

253 esponsive to more than 2 weeks of lithium or valproate therapy, were randomized to receive cotherapy

254 Valproate time and concentration dependently increased a

255 rs after menarche (177 lamotrigine, (HA) 186 valproate) to exclude OD the confounding effect of puber

256 s attenuated in hippocampus from lithium- or valproate-treated animals in vivo.

257 ence interval [CI] 0.78-0.95) but not during valproate treatment (hazard ratio 1.02, 95% CI 0.89-1.15

258 Participants were randomly assigned to valproate treatment at a target dose of 10 to 12 mg per

259 Valproate treatment did not delay emergence of agitation

260 In addition, lithium or valproate treatment promotes neurogenesis, neurite growt

261 Lithium and valproate, two structurally different anti-bipolar drugs

262 In the absence of GABA, valproate (up to 50 mm) had no noticeable effect on the

263 The association between valproate use and IQ was dose dependent.

264 The local diffusion constants for valproate/valproic acid along the bilayer normal are fou

265 When valproate (VPA) (2 mmol/kg) or MS-275 (0.015-0.12 mmol/k

266 rs in children exposed to monotherapy sodium valproate (VPA) (6/50, 12.0%; aOR 6.05, 95%CI 1.65 to 24

267 combination of atypical antipsychotics with valproate (VPA) (a histone deacetylase inhibitor that ma

268 tam (LEV) 1.00 (0.16 to 1.84) p=0.02; sodium valproate (VPA) 0.74 (0.10 to 1.38) p=0.02; topiramate (

269 Sodium valproate (VPA) administered to neonatal mice causes cog

270 Valproate (VPA) and lithium, widely used for the treatme

271 The HDACIs sodium butyrate (NaB), valproate (VPA) and suberoylanilide hydroxamic acid (SAH

272 Valproate (VPA) can suppress absence and other seizures,

273 reviously shown that the anticonvulsant drug valproate (VPA) depletes inositol by inhibiting myo-inos

274 Valproate (VPA) is a commonly prescribed mood stabilizer

275 Valproate (VPA) is one of the most widely used drugs for

276 Valproate (VPA) is one of the two drugs approved by the

277 Sodium valproate (VPA) is widely used throughout the world to t

278 stration of the antimanic agents lithium and valproate (VPA) reduced synaptic AMPA receptor GluR1/2 i

279 of the histone deacetylase (HDAC) inhibitor valproate (VPA) with atypical antipsychotics has become

280 The mechanism of action of valproate (VPA), a widely prescribed short chain fatty a

281 One proposed adjunctive therapy is sodium valproate (VPA), an anticonvulsant known to promote neur

282 ctrum disorder among 432 children exposed to valproate was 4.15% (95% CI, 2.20%-7.81%) (adjusted HR,

283 Valproate was associated with poorer cognitive outcomes.

284 es) were associated with the lowest risk and valproate was associated with the highest risk (10.93% i

285 e reduction in synaptic GluR1 by lithium and valproate was attributable to a reduction of surface Glu

286 We aimed to establish whether lithium plus valproate was better than monotherapy with either drug a

287 of the study recruited 716 patients for whom valproate was considered to be standard treatment.

288 nts with an idiopathic generalised epilepsy, valproate was significantly better than both lamotrigine

289 For time to 12-month remission valproate was significantly better than lamotrigine over

290 For time to treatment failure, valproate was significantly better than topiramate (haza

291 f suicide-related events between lithium and valproate was statistically significant.

292 Women with IGE receiving valproate were at highest risk for anovulatory cycles, p

293 High doses of valproate were negatively associated with IQ (r=-0.56, p

294 e, carbamazepine, lamotrigine, phenytoin, or valproate) were enrolled from October 14, 1999, through

295 at the protypical drugs for BPD--lithium and valproate--when administered in therapeutically relevant

296 noninfected BL-41 cells were incubated with valproate, whereas apoptosis occurred in response to val

297 Pharmaceutical agents such as valproate, which counteract the effects of genetically d

298 these mice the histone deacetylase inhibitor valproate, which increases acetylated histone content in

299 irus responded to the antiseizure medication valproate with entry into the lytic cascade and producti

300 le in contrast with 10.7% of women not using valproate within the preceding 3 years.